|
24 Haymarket
|
London
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC)
|
$0 - $5 million, $5 - $10 million, $15 - $20 million, Over $20 million
|
Europe
|
505(b)1
|
Under $1 million, $1 - 3 million, $3 - 5 million, $5 - 15 million
|
Therapeutic R&D, Diagnostic, Medical Device
|
Seed, Series A, Series B-Z
|
blood-borne diseases, in-vitro liver and metabolic disease, degenerative diseases, harmful cells, ba...
|
Cell therapies, Small molecules and peptides
|
Headquartered in London and with a regional office in Edinburgh, we are distinguished by the calibre...
|
|
4BIO Capital
|
London
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC)
|
$5 - $10 million, $10 - $15 million, $15 - $20 million, Over $20 million
|
Europe, North America, Asia
|
505(b)1
|
Under $1 million, $1 - 3 million, $3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D
|
Seed, Series A, Series B-Z, IPO or Public
|
all monogenic disorders, gain-of-function disorders, oncology, autoimmune disorders, genetic disease...
|
Cell therapies, Gene therapies, Large molecules (biologics), Small molecules and peptides, Microbiom...
|
4BIO Capital is a London-based venture capital firm focused solely on the advanced therapies sector....
|
|
5AM Ventures
|
Menlo Park
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC)
|
Over $20 million, $0 - $5 million, $10 - $15 million, $15 - $20 million
|
Europe, North America
|
505(b)1
|
$3 - 5 million, $5 - 15 million, Over $15 million, $1 - 3 million
|
Therapeutic R&D, Diagnostic, Medical Device, Other life science
|
Seed, Series A, Series B-Z, IPO or Public
|
brain disorders, inflammatory, metabolic, neurological diseases, rare diseases that target the endoc...
|
Cell therapies, Gene therapies, Large molecules (biologics), Small molecules and peptides, Vaccines,...
|
5AM Ventures is a leading venture capital firm focused on building next-generation life science comp...
|
|
8VC
|
San Francisco
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
Over $20 million, $0 - $5 million, $5 - $10 million, $10 - $15 million, $15 - $20 million
|
Europe, North America, Middle East Africa Rest of the World
|
505(b)1
|
$5 - 15 million, Over $15 million, Under $1 million, $1 - 3 million, $3 - 5 million
|
Therapeutic R&D, Diagnostic, Medical Device, Other life science
|
Seed, Series A, Series B-Z, IPO or Public
|
cancer, autoimmune diseases, immuno-oncology, liver cancer, colon cancer, lung cancer, breast cancer...
|
Cell therapies, Gene therapies, Large molecules (biologics), Small molecules and peptides, Microbiom...
|
At 8VC, we partner with elite founders to build transformational technologies that create long-term ...
|
|
A16z
|
Menlo Park
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC)
|
$5 - $10 million, $10 - $15 million, $15 - $20 million, Over $20 million
|
North America
|
505(b)1
|
$1 - 3 million, $3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D, Medical Device
|
Seed, Series A, Series B-Z, IPO or Public
|
cancer, autoimmune, oncology, monogenic diseases, inflammatory diseases, immunology, urea cycle diso...
|
Cell therapies, Gene therapies, Large molecules (biologics), Protein degradation, Small molecules an...
|
Andreessen Horowitz (aka a16z) is a venture capital firm that backs bold entrepreneurs building the ...
|
|
AbbVie Biotech Ventures
|
San Francisco CA, Cambridge MA, United Kingdom
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC)
|
Over $20 million
|
Europe, North America
|
505(b)1
|
Under $1 million, $1 - 3 million, $3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D, Diagnostic
|
Seed, Series A, Series B
|
gastro-intestinal diseases, Cancer, Solid Tumor, Prostate Cancer, Diabetes, Crohn's disease, ulcerat...
|
Cell therapies, Gene therapies, Protein degradation, Small molecules and peptides
|
AbbVie Ventures
As tomorrow’s innovations are developed by today’s entrepreneurs, we invest in trans...
|
|
Abingworth
|
London
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
$10 - $15 million, $15 - $20 million, Over $20 million
|
Europe, North America
|
505(b)1
|
$3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D, Medical Device, Other life science
|
Seed, Series A, Series B-Z, IPO or Public
|
rare diseases that target the endocrine system, chronic kidney disease, bacterial infections and vir...
|
Cell therapies, Gene therapies, Large molecules (biologics), Microbiome therapies, Protein degradati...
|
We strive to foster the creation of important new treatments for patients.
We follow a multi-pronge...
|
|
Acorn Bioventures
|
New York
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
Over $20 million, $15 - $20 million
|
Europe, North America
|
505(b)1
|
$5 - 15 million, Over $15 million
|
Therapeutic R&D, Medical Device
|
Seed, Series A, Series B-Z, IPO or Public
|
dermatologic conditions, cancer, immuno-oncology, Parkinson's disease, Alzheimer's disease, oncology...
|
Cell therapies, Gene therapies, Large molecules (biologics), Small molecules and peptides
|
Acorn Bioventures invests across stages in small-cap public and private biotechnology companies focu...
|
|
Adage Capital Management
|
Boston
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC), Commercial
|
$10 - $15 million, Over $20 million, $15 - $20 million
|
Asia, Europe, North America
|
505(b)1
|
$1 - 3 million, $3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D, Medical Device
|
Series B-Z, IPO or Public, Series A
|
cancer, oral immunology, autoimmune, inflammatory disorders, neurodegenerative, viral diseases, card...
|
Cell therapies, Gene therapies, Large molecules (biologics), Microbiome therapies, Small molecules a...
|
Adage Capital Management focuses on managing S&P 500 assets predominantly for endowments and foundat...
|
|
Aditum Bio
|
San Francisco
|
Both / no preference
|
Preclinical, Early-stage clinical (pre-POC), Discovery
|
$15 - $20 million, Over $20 million
|
North America
|
505(b)1
|
Over $15 million
|
Therapeutic R&D, Diagnostic, Medical Device
|
Series A
|
obesity, cardiometabolic disease, HIV, hepatitis b, hepatitis c, obesity, depression, substance abus...
|
Cell therapies, Gene therapies, Small molecules and peptides
|
Drug development has reached an inflection point. Legacy drug development models are falling short i...
|
|
Advent Life Sciences
|
London
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
$0 - $5 million, $5 - $10 million, $10 - $15 million, $15 - $20 million, Over $20 million
|
North America, Europe
|
505(b)1
|
$1 - 3 million, $3 - 5 million, $5 - 15 million
|
Therapeutic R&D, Medical Device
|
Seed, Series A, Series B-Z
|
cancer, osteoarthritis, inflammatory diseases, autoimmune, neurodegenerative disorders, life-threate...
|
Gene therapies, Microbiome therapies, Small molecules and peptides, Vaccines
|
Advent Life Sciences is one of the leading trans-Atlantic venture investors focused on building inno...
|
|
Agent Capital
|
Cambridge
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
$5 - $10 million, $10 - $15 million, $15 - $20 million, Over $20 million
|
Europe, North America
|
505(b)1
|
Under $1 million, $1 - 3 million, $3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D, Diagnostic
|
Seed, Series A, Series B-Z
|
cancer, tumor, autoimmune disease, inflammatory disease, fibrotic disease, metabolic disease, hemoph...
|
Cell therapies, Gene therapies, Large molecules (biologics), Small molecules and peptides, Vaccines
|
Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated the...
|
|
Aglaia Oncology Funds
|
Bilthoven
|
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
|
|
505(b)1
|
|
Therapeutic R&D, Diagnostic, Medical Device
|
IPO or Public
|
cancer, oncology, prostate cancer, breast cancer, solid tumors, cervical cancer, chronic HBV, COVID-...
|
Cell therapies, Large molecules (biologics), Small molecules and peptides
|
Aglaia Oncology Funds is a financial service company that provides investment funds in the research ...
|
|
Aisling Capital
|
New York
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC), Commercial
|
Over $20 million
|
Europe, North America
|
505(b)1
|
$3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D, Medical Device
|
Series A, Series B-Z, IPO or Public
|
cancer, migraine, psychiatric disorders, narcolepsy, central nervous system disorders, oral desensit...
|
Cell therapies, Gene therapies, Large molecules (biologics), Microbiome therapies, Small molecules a...
|
Aisling Capital seeks to identify differentiated healthcare products, services and technologies that...
|
|
Alaska Permanent Fund
|
Juneau
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC)
|
Over $20 million
|
North America
|
505(b)1
|
Over $15 million
|
Therapeutic R&D, Medical Device, Other life science
|
Series A, Series B-Z
|
genetic diseases, autoimmune, metabolic, oncology, infectious disease, immunology, diabetes, CNS, li...
|
Cell therapies, Gene therapies, Large molecules (biologics), Small molecules and peptides
|
Viewed as one of the largest, most effective, and globally-positioned institutional investors among ...
|
|
Alexandria Venture Investments
|
Pasadena
|
Both / no preference
|
Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
Over $20 million
|
Europe, North America
|
505(b)1
|
$5 - 15 million, Over $15 million
|
Therapeutic R&D, Diagnostic, Medical Device
|
Seed, Series A, Series B-Z, IPO or Public
|
Atherosclerosis, Psoriasis/Rheumatoid Arthritis, Sepsis, Inflammatory Bowel Disease, Cancers, Tumors...
|
Cell therapies, Gene therapies, Large molecules (biologics), Protein degradation, Small molecules an...
|
To create and grow life science ecosystem and clusters that ignite and accelerate the world's leadin...
|
|
Ally Bridge
|
Hong Kong
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
$10 - $15 million, Over $20 million
|
North America, Asia
|
505(b)1
|
$5 - 15 million, Over $15 million
|
Therapeutic R&D, Diagnostic, Medical Device
|
Series A, Series B-Z, IPO or Public
|
cancer, back pain, serious disease, nasal breathing, pulmonary fibrosis, autoimmune, Alzheimer, Park...
|
Cell therapies, Gene therapies, Large molecules (biologics), Radiopharmacueticals, Small molecules a...
|
We invest across the global healthcare industry and investments are made across the capital structur...
|
|
Altitude Life Science Ventures
|
Durango
|
Both / no preference
|
Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
Over $20 million
|
North America
|
505(b)1
|
$5 - 15 million, Over $15 million
|
Therapeutic R&D
|
Series A, Series B-Z
|
Chronic Inducible Urticaria, Atopic Dermatitis, Cholestatic Pruritus, Alzheimer’s, Schizophrenia, Pa...
|
Cell therapies, Gene therapies, Protein degradation, Small molecules and peptides
|
Altitude Life Science Ventures seeks opportunities to invest in early stage life science companies w...
|
|
Amgen Ventures
|
San Francisco
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC)
|
$5 - $10 million, $10 - $15 million, $15 - $20 million, Over $20 million
|
North America, Europe, Asia
|
505(b)1
|
Under $1 million, $1 - 3 million, $3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D, Diagnostic, Medical Device, Other life science
|
Seed, Series B-Z, IPO or Public, Series A
|
solid tumors, heme, osteoporosis, cardiometabolic diseases, autoimmune, inflammatory disorders, chro...
|
Cell therapies, Gene therapies, Large molecules (biologics), Small molecules and peptides, Vaccines
|
Amgen is harnessing our world-class capabilities to deliver more value to those we serve—providing b...
|
|
AmorChem Ventures
|
Montréal
|
Follower investors / prefers to follow
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
$10 - $15 million, Over $20 million
|
North America
|
505(b)1
|
$1 - 3 million, $5 - 15 million
|
Therapeutic R&D
|
Seed, Series A, Series B-Z
|
colon, terminal ileum, diabetic kidney disease, metabolic syndrome. idiopathic pulmonary disease
|
Small molecules and peptides
|
AmorChem is a leading early stage venture fund dedicated to creating the next generation of biotech ...
|
|
Amplitude Venture Capital
|
Montreal
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
$5 - $10 million, $10 - $15 million, $15 - $20 million, Over $20 million
|
North America, Middle East Africa Rest of the World
|
505(b)1
|
$1 - 3 million, $3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D
|
Series A, Series B-Z, IPO or Public
|
inflammatory diseases, cancer, auto-immune, infectious diseases, genetic metabolic diseases, rare ge...
|
Cell therapies, Gene therapies, Large molecules (biologics), Small molecules and peptides
|
We are savvy investors and proven company builders who, at the core, are driven to bring the best he...
|
|
Andera Partners
|
Paris
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
Over $20 million
|
Europe, North America
|
505(b)1
|
$3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D, Medical Device
|
Seed, Series A, Series B-Z, IPO or Public
|
autoimmune, rare diseases, neuroendocrine, hard-to-treat cancers, congestive heart failure, rare end...
|
Cell therapies, Large molecules (biologics), Radiopharmacueticals, Small molecules and peptides, Vac...
|
We currently manage €4 billion, invested in around 300 companies in Europe and the United States. We...
|
|
Angelini Ventures
|
Rome
|
Follower investors / prefers to follow
|
Discovery
|
$5 - $10 million, Over $20 million
|
Europe, North America
|
505(b)1
|
$1 - 3 million, $5 - 15 million
|
Therapeutic R&D, Medical Device, Other life science
|
Seed, Series A
|
CNS disorders, neurodevelopmental disorders, mental health, epilepsy, brain disorders, aging,
|
Gene therapies, Small molecules and peptides
|
We build and invest in companies that positively impact human health with smart solutions, breakthro...
|
|
Apollo Health Ventures
|
Berlin
|
Both / no preference
|
Discovery, Preclinical
|
$0 - $5 million, $5 - $10 million, $10 - $15 million, $15 - $20 million, Over $20 million
|
Europe, North America
|
505(b)1
|
Under $1 million, $1 - 3 million, $3 - 5 million, $5 - 15 million
|
Therapeutic R&D
|
Seed, Series A
|
age-related diseases, rare diseases, heart failure diseases, neurological disorders, rare genetic an...
|
Cell therapies, Gene therapies, Microbiome therapies, Small molecules and peptides
|
Apollo Health Ventures is a transatlantic early stage Venture Capital firm actively co-founding and ...
|
|
Arboretum Ventures
|
Ann Arbor
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC)
|
$0 - $5 million, $5 - $10 million, $10 - $15 million, $15 - $20 million, Over $20 million
|
North America
|
505(b)1
|
$1 - 3 million, $3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D, Diagnostic, Medical Device, Other life science
|
Seed, Series A, Series B-Z, IPO or Public
|
lymphedema or venous diseases, prostate cancer, kidney disease, bladder cancer, glaucoma, breast can...
|
Cell therapies, Gene therapies, Small molecules and peptides, Large molecules (biologics)
|
A healthcare venture capital firm rooted in the Midwest
Our progressive strategy of investing in un...
|
|
ARCH Venture Partners
|
Chicago
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
Over $20 million
|
Asia, Europe, North America
|
505(b)1
|
$3 - 5 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D, Diagnostic, Medical Device
|
Seed, Series A, Series B-Z, IPO or Public
|
neurological disorders, cancer, metastatic cancers, cardiovascular disease, autoimmune diseases, liv...
|
Cell therapies, Gene therapies, Large molecules (biologics), Small molecules and peptides, Vaccines
|
We’re catalyzing discoveries that prevent, detect, and cure disease.
Over 30 years, ARCH has backed...
|
|
Arix Bioscience
|
London
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
Over $20 million
|
Europe, North America
|
505(b)1
|
$3 - 5 million, $5 - 15 million
|
Therapeutic R&D
|
Series A, Series B-Z, IPO or Public
|
immuno-oncology, hematologic diseases, rare blood disorders, inflammatory diseases, cancer, tumors, ...
|
Gene therapies, Large molecules (biologics), Small molecules and peptides, Vaccines, Cell therapies
|
We focus on investing in and building breakthrough biotech companies around cutting edge advances in...
|
|
Arkin Bio Ventures
|
Herzliya
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC)
|
$10 - $15 million, $15 - $20 million, Over $20 million
|
North America, Middle East Africa Rest of the World
|
505(b)1
|
$1 - 3 million, $3 - 5 million, $5 - 15 million
|
Therapeutic R&D, Medical Device
|
Seed, Series A, Series B-Z
|
endogenous disease-fighting mechanisms, liver diseases, viral diseases, cancer, tumor, myelodysplast...
|
Cell therapies, Large molecules (biologics), Small molecules and peptides
|
Arkin Holdings is dedicated to empowering companies that create breakthrough pharma, biotech, medica...
|
|
Astellas Venture Management
|
Menlo Park
|
Both / no preference
|
Discovery, Preclinical
|
$5 - $10 million, $10 - $15 million, $15 - $20 million, Over $20 million
|
Asia, Europe, North America
|
505(b)1
|
$1 - 3 million, $3 - 5 million, $5 - 15 million
|
Therapeutic R&D, Medical Device
|
Seed, Series A, Series B-Z
|
cancer, immunology, autoimmunity, tumors, oncology, ophthalmology, metabolic, otology, genetic disea...
|
Cell therapies, Gene therapies, Large molecules (biologics), Small molecules and peptides
|
AVM is the wholly-owned venture capital organization within Astellas, dedicated to supporting pre-cl...
|
|
Atai Life Sciences
|
Munich
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC), Commercial
|
Over $20 million
|
Europe, North America
|
505(b)1
|
$5 - 15 million
|
Therapeutic R&D, Medical Device, Other life science
|
Series B-Z, IPO or Public
|
migraine, erectile dysfunction, schizophrenia, neurodegenerative brain diseases, opoid dependence, c...
|
Large molecules (biologics), Small molecules and peptides
|
We are a biopharmaceutical company that leverages a decentralized platform approach to incubate and ...
|
|
ATEM Capital Fund LP
|
New York
|
Follower investors / prefers to follow
|
Discovery, Preclinical, Early-stage clinical (pre-POC)
|
$15 - $20 million, Over $20 million
|
Europe, North America
|
505(b)1
|
$1 - 3 million, $3 - 5 million, $5 - 15 million
|
Therapeutic R&D
|
Series A, Series B-Z
|
rare endocrine, metabolic disorders, cancer, Hypoparathyroidism, Acromegaly, Humoral hypercalcemia o...
|
Cell therapies, Large molecules (biologics), Small molecules and peptides
|
INVESTMENTSATEM Capital invests in innovations across the Life Sciences industry with the promise to...
|
|
Avalon Ventures
|
La Jolla
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC)
|
Over $20 million
|
North America
|
505(b)1
|
$5 - 15 million
|
Therapeutic R&D, Medical Device, Other life science
|
Series A, Series B-Z, Seed
|
tumor, cancer, immune-mediated, neurological diseases,
myeloproliferative disorders, lung cancer,
...
|
Small molecules and peptides, Gene therapies, Large molecules (biologics), Peptide therapeutics, Vac...
|
Avalon Ventures is a venture capital firm that has founded and/or funded more than 100 information t...
|
|
Atlas Venture
|
Cambridge
|
Both / no preference
|
Discovery, Preclinical, Early-stage clinical (pre-POC), Late-stage clinical (post-POC)
|
$10 - $15 million, $15 - $20 million, Over $20 million
|
Europe, North America
|
505(b)1
|
$1 - 3 million, $5 - 15 million, Over $15 million
|
Therapeutic R&D, Medical Device
|
Seed, Series A, Series B-Z, IPO or Public
|
non-alcoholic steatohepatitis, cancer, myeloma, retinal disorders, hematologic diseases, rare blood ...
|
Cell therapies, Gene therapies, Large molecules (biologics), Protein degradation, Radiopharmacuetica...
|
Biotech venture creation is a team endeavor.
Atlas Venture creates and invests in biotech startup c...
|
